Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas
Status:
Completed
Trial end date:
2020-06-12
Target enrollment:
Participant gender:
Summary
Single center, phase I/II trial of pembrolizumab after CTL019 for CD19+ lymphomas. Patients
will have CD19+ diffuse large B-cell, follicular, or mantle cell lymphomas
relapsed/refractory after CTL019. 12 total patients will be enrolled. Safety of pembrolizumab
(primary endpoint) will be determined using a Bayesian monitoring rule for treatment-related
adverse events causing drug discontinuation. Secondary efficacy endpoints include overall
response rate and progression-free survival.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania